Vicki Higham Joins Neurobiological Technologies as Clinical Project Manager for Acute Ischemic Stroke Program
May 15 2007 - 10:00AM
PR Newswire (US)
EDGEWATER, N.J., May 15 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (NASDAQ:NTII) announced today that
Vicki Higham, MSN, RN, has joined the company as Clinical Project
Manager. Ms. Higham will manage the clinical operations program for
Viprinex(TM) (ancrod), a reperfusion agent currently in Phase III
development for acute ischemic stroke. Ms. Higham was the Study
Delivery Leader for the U.S. portion of AstraZeneca's SAINT-II
study for acute ischemic stroke. Warren W. Wasiewski, M.D.,
F.A.A.P., Vice President of Clinical Programs, said, "We are very
pleased to have Ms. Higham who we expect will play a key role in
NTI's Viprinex Phase III program. Ms. Higham brings twenty-three
years of critical care nursing experience and almost ten years of
clinical trial experience to NTI. This is a pivotal time in the
company's history, and her expertise in the field of stroke
clinical trials is an excellent addition to our already strong
clinical team." Ms. Higham holds a Bachelor of Science degree in
Nursing from Wilmington College and a Masters of Science degree as
a Clinical Nurse Specialist in Adult Health from Widener
University. About Neurobiological Technologies, Inc. NTI is a
biotechnology company engaged in the business of acquiring and
developing central nervous system related drug candidates. The
Company is focused on therapies for neurological conditions that
occur in connection with ischemic stroke and brain cancer. The
Company's strategy is to in-license and develop later-stage drug
candidates that target major medical needs and that can be rapidly
commercialized. NTI's experienced management team oversees the
human clinical trials necessary to establish preliminary evidence
of efficacy. Forward-Looking Statements Except for the historical
information contained herein, the matters discussed in this press
release are forward-looking statements that involve risks and
uncertainties, including: our need for additional capital, risks
relating to the regulatory approval and commercialization of
Viprinex, the inherent risk of failure in developing product
candidates based on new technologies, the risks associated changes
in our management team and other risks detailed from time to time
in our Annual Report of Form 10-K and other filings with the
Securities and Exchange Commission. Actual results may differ
materially from those projected. These forward-looking statements
represent our judgment as of the date of the release. We undertake
no obligation to update these forward-looking statements.
DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Warren W.
Wasiewski, M.D., F.A.A.P., Vice President of Clinical Programs of
Neurobiological Technologies, Inc., +1-201-941-5000 Web site:
http://www.ntii.com/
Copyright
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Jul 2023 to Jul 2024